Table 1.
Summary of islet T cell donors
| Groupa | Donor group | Number of donors | Gender (M:F) | Age (median, range) | Time from diagnosis (median, range) | HLA DRB1 | Sample type | Sample source | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DR4/ DR4 | DR4/ DR3 | DR4/ other | DR3/ DR3 | DR3/ other | other/ other | ||||||||||
| PITb T cells | T1D | 14 | 5:9 | 19 y (3-28) | 2 y (0.3-15) | 0 | 4 | 5 | 1 | 2 | 2 | Pancreas | nPOD, ADI, VUMC/ Pittsburgh | ||
| 1 Aab+ | 4 | 2:2 | 21 y (19-29) | -- | 0 | 0 | 1 | 0 | 2 | 1 | Pancreas | nPOD | |||
| non-T1D control | 9 | 6:3 | 30 y (18-34) | -- | 1 | 1 | 0 | 1 | 2 | 4 | Pancreas | nPOD, ADI, IIDP | |||
| IAR Cohort 1c | T1D | 12 | 8:4 | 27 y (10-40) | 3.6 y (1.6-7.1) | 3 | 2 | 7 | 0 | 0 | 0 | PBMC | BRI Registry, TrialNet | ||
| newT1D | 24 | 13:11 | 19 y (12-34) | <100d | 4 | 6 | 9 | 0 | 5 | 0 | PBMC | ITN | |||
| HC | 12 | 8:4 | 28 y (13-38) | -- | 0 | 2 | 10 | 0 | 0 | 0 | PBMC | BRI Registry | |||
| IAR Cohort 2 | newT1D | 11 | 5:5 (1 NA) | 19 y (12-28) | <100d | 1 | 5 | 3 | 0 | 2 | 0 | PBMC | ITN | ||
| 1 Aab+d | 8 | 3:5 | 29 y (11-52) | -- | 0 | 0 | 4 | 2 | 2 | 0 | PBMC | TrialNet | |||
| >1 Aab+d | 6 | 2:4 | 19 y (15-45) | -- | 2 | 1 | 1 | 0 | 1 | 1 | PBMC | TrialNet | |||
| noAAb (HC) | 6 | 5:1 | 20 y (14-39) | -- | 0 | 1 | 2 | 0 | 2 | 1 | PBMC | BRI Registry | |||
a A more detailed description of individual donors is shown in Supplementary Data 1
b PIT pancreatic infiltrating T cells, T1D >1 year from T1D onset, newT1D <100 days from T1D onset, Aab autoantibody, nPOD Network for Pancreatic Organ Donors with Diabetes, ADI Alberta Diabetes Institute Islet Core, VUMC/Pittsburgh Vanderbilt University Medical Center/University of Pittsburgh, IIDP Integrated Islet Distribution Program, BRI Benaroya Research Institute, ITN Immune Tolerance Network.
c Donors in Cohort 1 were included our previous studies (PMID: 37886513).
d 1 IAR AAb+ and >1 AAb+ donors were pooled together into a single AAb+ group for analysis